ASCO 2014 - Featured Videos

Chemohormonal Therapy vs. Hormonal Therapy for Hormone-sensitive mPrCa

Details
ASCO 2014 - Impact on Overall Survival (OS) with Chemohormonal Therapy vs. Hormonal Therapy for Hormone-sensitive Newly Metastatic Prostate Cancer (mPrCa): An ECOG-led Phase III Randomized Trial Christopher Sweeney, MD Dana-Farber Cancer Institute SEE RELATED CONTENT Read an exclusive report by a UroToday medical writer View a slide presentation by Dr. Sweeney Insights into E3805: The CHAARTED tri...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe